A prospective study of neoadjuvant pembrolizumab plus chemotherapy for resectable esophageal squamous cell carcinoma: The Keystone-001 trial
Xiaobin Shang, Yongjie Xie, Jinpu Yu, Chen Zhang, Gang Zhao, Fei Liang, Liang Liu, Wei‐Hong Zhang, Runmei Li, Wenwen Yu, Jie Yue, Chuangui Chen, Xiaofeng Duan, Zhao Ma, Zuoyu Chen, Yanjuan Xiong, Fan Yang, Jianyu Xiao, Rui Zhang, Pengpeng Liu, Yanan Cheng, Fuliang Cao, Feng Guo, Guoyan Liu, Bin Meng, Dejun Zhou, Yan Sun, Xiubao Ren, Jun Yu, Jihui Hao, Hongjing Jiang, Jihui Hao, Hongjing Jiang
Topics & Concepts
PembrolizumabEsophageal squamous cell carcinomaMedicineChemotherapyOncologyInternal medicineNeoadjuvant therapyCarcinomaImmunotherapyCancerBreast cancerEsophageal Cancer Research and TreatmentCancer Immunotherapy and BiomarkersPancreatic and Hepatic Oncology Research